Click the star to add/remove an item to/from your individual schedule.
You need to be logged in to avail of this functionality.

P01


Ambivalent objects: things, substances, commodities, and technologies in Global Health 
Convenors:
Andrew Russell (Durham University)
Tom Widger (Durham University)
Location:
FUL-104
Start time:
10 September, 2015 at
Time zone: Europe/London
Session slots:
3

Short Abstract:

Drawing from recent theoretical work concerning ‘things,’ this panel traces the ambivalence of objects, substances, commodities, and technologies that play crucial roles in the promotion or degradation of global health – and the technological assemblages that help to disperse them.

Long Abstract:

Recent years have seen a burgeoning interest in materials and manufactures as they relate to health, illness and disease. Pharmaceutical products, substances such as drugs, alcohol and tobacco, other chemical compounds with ambiguous health implications such as pesticides and plastics, and the technological assemblages that help to disperse them: all are pregnant with theoretical and practical implications. Objects can do many things - attract and repel, kill and cure, help and hinder, benefit and disadvantage, problematize and solve. Sometimes they can do these things simultaneously, sometimes sequentially. Sometimes they do nothing at all. Such is the ambivalence of the object and its position in human and non-human life. This panel invites papers that consider the history and contemporary configurations of the non-human, material world in and of global health. We are particularly interested in contributions that address one or more of the current theoretical approaches to objects, for example material culture studies, thing-theory, ANT, speculative realism, and post-phenomenology. How do concepts like ‘agency’, ‘biography,’ ‘thing-power’, ‘actant’ and ‘assemblage’ better enable us to address issues concerning human health, illness and wellbeing at the global level? What is the relationship between objects, people and corporations, and how do these change along global commodity (value) chains? What does it mean, for example, to talk of a ‘pharmaceutical person’ (Martin 2006), to take an ‘object’s-eye view’, or to ‘follow the thing’? ‘Can the thing speak?’ (Holbraad 2011) in a more than ventriloquistic fashion, and, if so, what things speak and what do they say?

Accepted papers:

Session 1